Currax Pharmaceuticals LLC is a patient-first pharmaceutical company focused on the number one and number two causes of preventable death in the United States: smoking and obesity. Currax is proud to celebrate being recognized as a 2022 Best Places to Work by Nashville Business Journal thanks to our talented and hard-working employees.



Contact Information
Christian Sinclair
[email protected]

Latest

Oct 19, 2023, 10:15 ET Currax Pharmaceuticals:CONTRAVE®/MYSIMBA® no demuestra un mayor riesgo de eventos cardíacos adversos

Currax Pharmaceuticals LLC ("Currax") anunció hoy los resultados de primera línea de un Análisis de resultados de salud cardiovascular (HOA). Este...

Oct 19, 2023, 10:10 ET Currax Pharmaceuticals: Přípravek CONTRAVE®/MYSIMBA® neprokázal zvýšené riziko závažných nežádoucích srdečních příhod v rozsáhlé dlouhodobé studii s údaji z reálné klinické praxe

Společnost Currax Pharmaceuticals LLC („Currax") dnes oznámila aktuální výsledky analýzy kardiovaskulárních zdravotních výsledků (Health Outcomes...

Oct 19, 2023, 09:47 ET Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® не несет повышенных рисков кардиальных явлений | Currax Pharmaceuticals: масштабные длительные исследования в реальных условиях CONTRAVE®/MYSIMBA® указывают на отсутствие признаков повышенного риска тяжелых нежелательных сердечно-сосудистых явлений

Сегодня компания Currax Pharmaceuticals LLC (далее «Currax») объявила о статистически значимых результатах анализа последствий для здоровья (HOA)...

Oct 18, 2023, 17:37 ET Currax Pharmaceuticals : CONTRAVE®/MYSIMBA® ne présente aucun risque accru d'événements cardiaques indésirables majeurs d'après une vaste étude à long terme sur des données réelles

Currax Pharmaceuticals LLC (« Currax ») a annoncé aujourd'hui les excellentes conclusions d'une analyse des résultats thérapeutiques (HOA)...

Oct 18, 2023, 15:35 ET Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® wykazuje brak zwiększonego ryzyka wystąpienia poważnych niepożądanych zdarzeń sercowych w ramach dużego, długoterminowego badania prowadzonego w warunkach praktyki klinicznej, ukierunkowanego na zgromadzenie dowodów

Spółka Currax Pharmaceuticals LLC ("Currax") ogłosiła dzisiaj wstępne wyniki oceny skutków zdrowotnych w zakresie układu krążenia. Badanie to miało...

Oct 18, 2023, 14:54 ET Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® nepreukazuje zvýšené riziko závažných nežiaducich srdcových príhod vo veľkej dlhodobej štúdii s reálnymi dôkazmi

Spoločnosť Currax Pharmaceuticals LLC („Currax") dnes oznámila hlavné závery analýzy výsledkov kardiovaskulárneho zdravia (HOA). V tejto štúdii sa...

Oct 18, 2023, 14:45 ET Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® zeigt in einer großen, langfristigen Real-World-Evidenz-Studie kein erhöhtes Risiko für schwerwiegende unerwünschte kardiale Ereignisse

Currax Pharmaceuticals LLC („Currax") gab heute die ersten Ergebnisse einer Cardiovascular Health Outcomes Analysis (HOA) bekannt. Diese Studie...

Oct 18, 2023, 12:52 ET Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® ha demostrado no aumentar el riesgo de eventos cardíacos adversos graves en un amplio estudio de evidencia del mundo real a largo plazo

Currax Pharmaceuticals LLC ("Currax") anunció hoy los resultados de primera línea de un Análisis de Resultados de Salud Cardiovascular (HOA). Este...

Oct 18, 2023, 12:43 ET Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® não demonstra grande risco nos principais eventos cardíacos adversos em um grande estudo baseado em evidências de mundo real de longo prazo

BRENTWOOD, Tennessee, 18 de outubro de 2023 /PRNewswire/-- A Currax Pharmaceuticals LLC ("Currax") anunciou hoje os resultados de linha superior de...

Oct 18, 2023, 08:00 ET Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study

Currax Pharmaceuticals LLC ("Currax") today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA). This study evaluated the ...

Oct 18, 2023, 08:00 ET Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study

Currax Pharmaceuticals LLC ("Currax") today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA). This study evaluated the ...

Mar 06, 2023, 09:00 ET Currax Files Lawsuit Against Found Health for False Marketing of Generic Equivalent of CONTRAVE®

Currax Pharmaceuticals LLC ("Currax"), a privately held specialty biopharmaceutical company dedicated to tackling the number one and number two...

Aug 29, 2022, 08:30 ET One Size Does Not Fit All™: Currax Pharmaceuticals Launches New Campaign to Address Emotional Eating Challenges Faced by Individuals Seeking Weight Loss

Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company and manufacturer of the #1 oral weight loss medication brand CONTRAVE®...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE